Neuromuscular Adverse Effect

Neuromuscular adverse effect encompasses muscle weakness, myalgia, and neuromuscular dysfunction. Statin-induced myopathy represents common drug-induced myopathy. Electromyography confirms neuromuscular involvement. Muscle biopsy identifies pathological changes. Reversibility upon drug discontinuation suggests drug causality.

Clinical monitoring detects early myopathy signs. Creatine kinase elevation indicates muscle injury. Dose reduction may preserve beneficial effects while reducing toxicity. Regulatory submissions highlight myopathy risks. Post-approval surveillance identifies myopathy patterns.